NGFN-PLUS
Evaluation of tools for clinical detection of mutations and copy number changes
Coordinator: | Prof. Dr. Peter Nürnberg | |
Institution: | Cologne Center for Genomics (CCG) | |
Homepage: | www.ccg.uni-koeln.de |
In the era of targeted cancer therapeutics, treatment decisions will increasingly be based on the genetic makeup of individual cancers, as opposed to their anatomic origins. This notion underscores the importance of a systematic characterization of cancer somatic genetic alterations. Moreover, as more targeted agents are designed, it will become equally important to develop molecular diagnostics that pinpoint in situ the tumors most likely to respond. Such tools will facilitate rational clinical trial design and, ultimately, individualized approaches to cancer treatment. In the first part we plan to benchmark the genetic diagnostic technologies with the greatest chance to provide somatic genetic diagnosis of clinical cancer specimens in real time in an everyday environment. In the second part we will use the most appropriate technologies to measure genetic lesions in patients receiving molecularly targeted treatment for their cancers in order to relate lesions to therapeutic outcome. Both parts will be accomplished in close interaction with SP 2 (Wolf).
KTT
MEDIA
CURRENT
NGFN-MEETING-2012
NGFN- MEETING
NGFN1&2
LINKS